Long-read genome sequencing and variant reanalysis increase diagnostic yield in neurodevelopmental disorders

3

4 Susan M. Hiatt^{1*}, James M.J. Lawlor¹, Lori H. Handley¹, Donald R. Latner¹, Zachary T. Bonnstetter¹, Candice R. Finnila¹, Michelle L. Thompson¹, Lori Beth Boston¹, Melissa Williams¹, 5 6 Ivan Rodriguez Nunez¹, Jerry Jenkins¹, Whitley V. Kelley¹, E. Martina Bebin², Michael A. 7 Lopez^{2,3,4}, Anna C. E. Hurst⁴, Bruce R. Korf⁴, Jeremy Schmutz¹, Jane Grimwood¹, Gregory M. 8 Cooper¹* 9 10 ¹HudsonAlpha Institute for Biotechnology, Huntsville, AL, 35806, USA 11 ²Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, 35924, USA 12 ³Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, 35924, USA 13 ⁴Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, 35924, USA 14 *shiatt@hudsonalpha.org, gcooper@hudsonalpha.org, 601 Genome Way, Huntsville, AL, 35806, 15 16 USA, 256-327-9490 17 18 19 **Running Title:** 20 Increased diagnostic yield with long-reads 21 22 Key Words: 23 LRS Special Issue, Long read sequencing, Clinical sequencing, neurodevelopmental disorder, 24 structural variation, repeat expansion 25

26 ABSTRACT

Variant detection from long-read genome sequencing (IrGS) has proven to be considerably more 27 28 accurate and comprehensive than variant detection from short-read genome sequencing (srGS). 29 However, the rate at which IrGS can increase molecular diagnostic yield for rare disease is not 30 yet precisely characterized. We performed IrGS using Pacific Biosciences "HiFi" technology on 31 96 short-read-negative probands with rare disease that were suspected to be genetic. We 32 generated hg38-aligned variants and *de novo* phased genome assemblies, and subsequently 33 annotated, filtered, and curated variants using clinical standards. New disease-relevant or 34 potentially relevant genetic findings were identified in 16/96 (16.7%) probands, eight of which 35 (8/96, 8.33%) harbored pathogenic or likely pathogenic variants. Newly identified variants were 36 visible in both srGS and IrGS in nine probands (~9.4%) and resulted from changes to 37 interpretation mostly from recent gene-disease association discoveries. Seven cases included 38 variants that were only interpretable in IrGS, including copy-number variants, an inversion, a 39 mobile element insertion, two low-complexity repeat expansions, and a 1 bp deletion. While 40 evidence for each of these variants is, in retrospect, visible in srGS, they were either: not called 41 within srGS data, were represented by calls with incorrect sizes or structures, or failed quality-42 control and filtration. Thus, while reanalysis of older data clearly increases diagnostic yield, we 43 find that IrGS allows for substantial additional yield (7/96, 7.3%) beyond srGS. We anticipate that 44 as IrGS analysis improves, and as IrGS datasets grow allowing for better variant frequency 45 annotation, the additional IrGS-only rare disease yield will grow over time.

46

47

49 INTRODUCTION

50 Although genome and exome sequencing (GS/ES) are increasingly used to identify molecular 51 causes of rare diseases, reported diagnostic rates range from 20-60% (Srivastava et al. 2019; 52 Baxter et al. 2022), indicating that many conditions suspected to be genetic remain refractory to 53 genomic testing. While some tested individuals may have phenotypes resulting from polygenic 54 and/or environmental risk factors (e.g., Niemi et al. 2018), a subset of undiagnosed cases likely 55 result from genetic factors that we are as-yet unable to identify. It is well-known that short-read 56 genome sequencing (srGS) has poor sensitivity to many types of variants, especially structural 57 variants (SVs) and variants affecting repetitive sequences (Wenger et al. 2019; Sanghvi et al. 58 2018; Mahmoud et al. 2024). Long-read genome sequencing (IrGS), in contrast, has been shown 59 to greatly improve sensitivity to many of the variants missed by srGS (Logsdon et al. 2020), in 60 addition to facilitating de novo assemblies to allow for more effective evaluation of structural 61 variation (Cheng et al. 2021). Accordingly, IrGS has great potential to improve rare disease 62 diagnostic testing and has been applied to several rare disease cohorts (Cohen et al. 2022; Miller 63 et al. 2021; Hiatt et al. 2021).

64 In addition to changes in sequencing technology, the scope of knowledge about genes 65 and our ability to annotate genetic variants has steadily increased. As such, systematic reanalysis 66 of GS/ES data also leads to the discovery of previously overlooked clinically relevant variants, 67 with diagnostic vield increases ranging from 4-31% depending on a variety of factors, most 68 notably time since the previous analysis (Hiatt et al. 2018; Liu et al. 2019; Schobers et al. 2022; 69 Hartley et al. 2023). While a variety of factors contribute to reanalysis discoveries, they often result 70 from the discovery of new disease genes, which contributes to 42-75% of reanalysis findings 71 (Hiatt et al. 2018; Liu et al. 2019; Schobers et al. 2022; Hartley et al. 2023). This reflects the rapid 72 pace of discovery of new disease genes in the rare disease research community, which has been

facilitated by data sharing via the MatchMaker Exchange and GeneMatcher (Philippakis et al.
2015; Sobreira et al. 2017).

Here we discuss findings from IrGS on a cohort of 96 short-read-negative cases, drawn from several studies focused on rare, suspected congenital diseases, especially early-onset neurodevelopmental disorders. We describe 19 relevant or potentially clinically relevant variants not previously evaluated or considered in 16 cases. We show that a combination of more comprehensive variant detection from IrGS and updated reanalysis contribute to these discoveries, supporting the value of a combination of IrGS and reanalysis as a strategy to maximize rates of discovery of highly penetrant variation leading to rare disease.

82

83 RESULTS

84 We selected individuals with rare diseases who had undergone short-read exome sequencing 85 (srES; n=2) or srGS (n=94) in previous research studies yet had no pathogenic or likely 86 pathogenic variants (P/LP) nor variants of uncertain significance (VUS) identified (Bowling et al. 87 2017; East et al. 2021; Bowling et al. 2022). Most of our cohort consisted of children (89% were 88 <18 years of age at time of enrollment) with a neurodevelopmental disorder (NDD, 70%), multiple 89 congenital anomalies (MCA, 22%), or a suspected genetic myopathy (8%). Probands consisted 90 of 66% males (63/96); genetically inferred ancestries for probands revealed 72% European 91 (69/96), 21% African/African American (20/96), 3% Admixed American (3/96), 1% Southeast 92 Asian (1/96) and 3% unspecified admixture ancestries (Table 1). For these 96 cases, we 93 performed IrGS using Pacific Biosciences "HiFi" sequencing to a median depth of 27X (Table 1, 94 Supplemental Table S1). For a subset (10/96), we also performed IrGS on parents (median 95 parental HiFi depth of 22X, Supplemental Table S2). We also generated *de novo* assemblies for 96 each proband using hifiasm (Cheng et al. 2021), with parental srGS used for kmer-based binning 97 and phasing when available. The median N50 for all proband contigs was 29.05 Mb (Table 1).

98

Table 1. Demographics, ar	nd sequencing and assembly metrics f	or the cohort		
Sex	Male	63 (66%)		
	Female	33 (34%)		
		=		
Predicted Major Genetic Ancestry	European (EUR)	71.88%		
	African (AFR)	20.83%		
	Admixed American (AMR)	3.13%		
	Southeast Asian (SAS)	1.04%		
	Unspecified Admixed (UNKNOWN)	3.13%		
		Median	Min	Мах
Sequencing Metrics	Sequenced Bases (Gb)	80.9	53.5	131.5
eequenenig meanee	Mean Read Length (Sequenced)	16,771	11,295	21,412
	Median Coverage (X)	27	18	44
	Percent Covered at 10x	97.80%	95.10%	99.00%
	Percent Covered at 20x	84.90%	36.10%	97.50%
Proband Assembly N50 (Mb)	All contigs	29.05	2.10	71.30
	Maternal contigs	29.30	2.10	71.30
	Paternal contigs	28.70	2.20	67.90
	hap1 contigs	31.70	18.20	42.90
	hap2 contigs	27.85	14.40	40.80
Small Variant Metrics (DeepVariant)	SNVs	4,404,564	3,997,350	5,299,670
	Total indels	970,031	926,286	1,153,616
Structural Variant Metrics (pbsv)	Total Structural Variants	55,586	53,834	65,120
,	Deletion	24,757	23,799	29,531
	Duplication	3,017	2,820	3,649
	Insertion	27,594	26,441	32,437
	Inversion	121	99	155
	Breakend	193	124	312

99

HiFi reads were aligned to hg38, and variant calling was performed using DeepVariant (Poplin et al. 2018) and pbsv (https://github.com/PacificBiosciences/pbsv, see Methods). A median of 4.4 million SNVs and 970,031 indels were called in each proband (Table 1).

103

104 Analysis of SVs

We detected a median of 55,586 SVs of varying classes across the 96 probands using pbsv (Table 1, Supplemental Table S3). We sought to characterize how filtering SVs by frequency could reduce manual curation burden by considering five allele frequency resources. First, we created a set of "cohort" SVs by performing SV call merging across all 96 probands using Jasmine (Kirsche et al. 2023) and generating allele counts from the merged set (set 1). We then used a second Jasmine merge step to match cohort SVs with SV frequencies from: an in-house set of

111 266 HiFi genomes including all cohort probands and parents, samples from other internal projects, 112 and public HiFi data (set 2, see Methods); gnomAD v4 SV frequencies from 63,046 short read 113 samples (set 3, Collins et al. 2020) Human Genome Structural Variant Consortium phase 2 114 (HGSVC2) assembly-based calls from 18 HiFi samples (set 4, Ebert et al. 2021); and a PacBio-115 provided set of pbsv calls from 103 HiFi samples from the Human Pangenome Reference 116 Consortium (HPRC) and Genome in a Bottle (GIAB) consortia (set 5, Ebert et al. 2021; 117 https://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/HGSVC2/release/v2.0/integrated_ca_ 118 llset/variants freeze4 sv insdel alt.vcf.gz;

119 https://github.com/PacificBiosciences/svpack/raw/main/resources/HPRC GIAB.GRCh38.pbsv.v

120 cf.gz). We note that these data are at least partially redundant with one another (e.g., set 1 is a 121 partial subset of set 2 and many public samples such as NA12878 are shared between sets 2-5). 122 However, our goal was to maximize filtering performance by including calls from as many datasets 123 and discovery methods as possible. When filtering SVs with this data, we found probands had a 124 median of 1,721 "rare" SVs, defined as having an allele frequency <1% in public SV databases 125 (sets 3-5) and an allele count <4 in the cohort or internal (sets 1 or 2). A subset of these (proband 126 median of 87 SVs) were within 50 bp of a RefSeq exon (Supplemental Table S3). We also filtered to identify "private" SVs as those absent from sets 3-5, having a set 1 allele count of 1, and having 127 128 a set 2 allele count of <= 2 (allowing for parental inheritance). This filtering results in a median of 129 733 SVs per proband, only 40 of which are within 50 bp of a RefSeq exon (Supplemental Table 130 S3).

131

132 Findings from IrGS

133 IrGS SNVs/indels were annotated with features such as gene overlaps, coding consequences, 134 computational impact scores, and allele frequencies. They were then filtered and analyzed using 135 in-house software that is also used for srGS data (Hiatt et al. 2021). Rare SVs were assessed by 136 visualization of reads in IGV and prioritization and analysis using SvAnna (Danis et al. 2022). All

Proban d ID	Gene(s) Affected	HGVS Nomenclature	Inheritance	Variant Classification	Case-Level Classification	ACMG/ClinGen Evidence Codes	SV, SNV or TRE	IrGS require d?	Orthogonal Validation
1	ZBTB20	NC_000003.12:g.110477273_114639202_inv	de novo	Р	Definitive Diagnostic	2A(+1.00), 5A (+0.15)	SV	Yes	Yes, Research Sanger of breakpoints
2	ALS2	NC_000002.12:g.201720435-201725085_del; NC_000002.12:g.200115181-201739349_del	biparental	LP; P	Definitive Diagnostic	2E (+0.90);2D-4 (+0.90), 3B (+0.45)	SVx2	Yes; Yes	Pending, supported by srGS data
3	HCFC1	NC_000023.11:g.153948602_ins4902, NM_005334.3:c.*745_ins4902	maternal (X-linked)	VUS	Uncertain	NA	SV	Yes	Yes, Research PCI amplification of breakpoints.
4	ABAT, PMM2, USP7, etc.	NC_000016.10:g.(8742452_9220783)ins[(87424 52_8879961)_(8879962_9000189)x2_(9000190 _9220783)]	de novo	VUS	Uncertain	2K (+0.30)	SV	Yes	Pending
5	PHOX2B	NM_003924.4:c.741_758dup, p.(Ala255_Ala260dup)	unknown [#]	Р	Definitive Diagnostic	PS4_M, PM1_Strong, PM2_Moderate, PM6_Moderate [#]	TRE	Yes	Yes, Clinical Testing*
6	AFF3	NM_001386135.1:c64-28164-280insGGC[90]	unknown	VUS	Uncertain	NA	TRE	Yes	Pending
7	SHANK3	NM_033517.1:c.3161delT, p.(Lys1054Argfs*10)	de novo	Р	Definitive Diagnostic	PVS1_VeryStrong, PS2_Strong, PM2 Moderate	SNV	Yes	Yes, Clinical Sange
8	HNRNPU	NM_031844.3:c.660_661dupAGGCGGCGGA, p.(Gly221ArgfsTer25)	de novo	Р	Definitive Diagnostic	PVS1_VeryStrong, PS2_Strong, PM2 Moderate	SNV	No	Yes, Clinical Sange
9	CSNK2B	NM_001320.6:c.202C>T, p.(Gln68Ter)	paternal	LP	Likely Diagnostic	PVS1_VeryStrong, PM2_Moderate	SNV	No	Yes, Clinical Sange
10	GNB2	NM_005273.4:c.217G>A, p.(Ala73Thr)	maternal	LP	Uncertain	PS4_Moderate, PP2_Supporting, PP3_Supporting	SNV	No	Yes, Clinical Sange
11	MCF2	NM_005369.5:c.2234G>T, p.(Gly745Val)	maternal (X-linked)	VUS	Uncertain	PM2	SNV	No	Yes, Clinical Sange
12	NOTCH3	NM_000435.3c.6409_6410delCT, p.(Leu2137GlyfsTer104)	paternal	LP	Likely Diagnostic	PVS1_Strong, PM2_Moderate	SNV	No	Yes, Clinical Sange
13	AFF4	NM_014423.4, c.879delÅ, p.(His294llefsTer5)	paternal	VUS	Uncertain	PM2	SNV	No	Yes, Clinical Sang
14	KCNT2, KIF21A	NC_000001.11:g.196329420-196344697_DUP, NM_017641.3:c.847C>T, p.(Arg283Cys); NM_017641.3:c.706C>T, p.(Gln236Ter)	paternal/ biparental	VUS, VUS;LP	Uncertain	2I (+0.45); PM2, PP3; PVS1, PM2	SV; SNV(x2)	No; No	SV Pending, supported by srG data; SNVs-Clinic Sanger
15	NRXN1	NC_000002.12:49922063_49928691del	de novo	VUS	Uncertain	2E (+0.30), 4C (+0.15), 4M (+0.30)	SV	No	Pending, supporte by srGS data
16	SCN1A	NM 001165963.4:c.4003-603T>C	paternal	VUS	Uncertain	PM2 Moderate	SNV	No	Yes, Clinical Sange

SV, Structural variant; SNV, single nucleotide variant; TRE, tandem repeat expansion. P, Pathogenic; LP, Likely Pathogenic; VUS, Variant of Uncertain Significance; NA, not applicable. #Independent clinical testing indicated that the *PHOX2B* expansion was de novo; we only sequenced the proband in our research study.

138 variants of interest were subject to curation using American College of Medical Genetics and 139 Genomics and Association for Molecular Pathology (ACMG/AMP) and ClinGen criteria to identify 140 potentially clinically relevant variation (Richards et al. 2015; Riggs et al. 2020). We identified 19 141 potentially "clinically relevant" variants, defined here as being pathogenic, likely pathogenic, or 142 variants of uncertain significance (P/LP/VUS), in 16 of the 96 cases (Table 2). Seven of these 143 have a case-level classification of Definitive Diagnostic or Likely Diagnostic, which we define as 144 P/LP variants that likely fully explain the reason for testing (Bowling et al. 2022). The remaining 145 nine cases have Uncertain case-level classifications, either due to the variants being VUSs or 146 being P/LP variants in genes whose associated phenotypes do not closely match the observed 147 phenotype. Findings in seven probands exemplify the unique benefits of IrGS and are highlighted 148 below.

149

150 IrGS-informed SVs

151 IrGS uncovered a *de novo*, 4 Mb, copy-neutral, paracentric inversion on chromosome 3 152 (NC 000003.12:g.110477273 114639202 inv) in Proband 1 (Figure 1). This inversion spans




Figure 1. A *de novo*, 4 Mb paracentric inversion in proband 1, affecting *ZBTB20*. A, B. Visualization of a subset of proband and parent reads in IGV at the 5' (A) and 3' (B) breakpoints (black arrowheads) indicate a *de novo* event. C. Alignment of the proband's assembled paternal contig versus the reference genome supports the inversion. D. Visualization of the inverted region (highlighted in light blue) in the UCSC browser shows the inversion spans 35 protein-coding genes and likely disrupts the *ZBTB20* gene (dark blue bar).

153 about 35 protein-coding genes, and one breakpoint of this inversion lies within an intron of ZBTB20 (MIM: 606025). The event breakpoints are visible in both long and short reads for this 154 155 proband, but it was only called as an inversion in IrGS. The variant is private to the proband and 156 is predicted to disrupt ZBTB20. Loss-of-function (LOF) variation in ZBTB20 is associated with 157 Primrose Syndrome (MIM: 259050) and 3q13.31 Microdeletion Syndrome (Juven et al. 2020). 158 Proband 1's reported features include moderate intellectual disability (ID), delayed speech and 159 language development, muscular hypotonia, strabismus, and hypoplastic corpus callosum. She 160 is also non-ambulatory. Several of these features overlap Primrose Syndrome. We have classified 161 this variant as pathogenic and the case-level designation is Definitive Diagnostic (Table 2).

162 Proband 2 presented with spasticity, ataxia, and leukodystrophy. srGS was negative, but 163 IrGS identified two structural variants (SVs) identified in trans in ALS2 (MIM: 606352). These 164 include a maternally-inherited 4.65 kb deletion (chr2:201720435-201725085 del) that removes 165 exons 21-23 of NM 020919.4, and a paternally-inherited ~1.6 Mb deletion (chr2:200115181-166 201739349 del) that spans several genes, including the 3' end of ALS2 (deletion of exons 12-34 167 of NM 020919.4, Figure 2, Table 2). While these variants are visible in short-read data, the 168 smaller deletion was called as a heterozygous deletion in the mother and as a homozygous deletion in the proband, obfuscating the nature of the variation and raising quality-control 169 170 concerns. Given the results of the IrGS, the srGS variant calls logically resulted from the small 171 maternal deletion intersecting with the larger, overlapping paternal deletion. This case highlights 172 the difficulties in identification and analysis of overlapping SVs of unknown phase. Variation in 173 ALS2 is associated with several AR conditions (Juvenile amyotrophic lateral sclerosis 2, MIM: 174 205100; Juvenile Primary lateral sclerosis, MIM: 606353; and infantile onset ascending Spastic 175 paralysis, MIM: 607225), each of which have features that overlap the proband's presentation.

- 176 These variants are classified as P/LP and, given the degree of overlap with expected phenotypes,
- 177 the case-level designation is Definitive Diagnostic.





Figure 2. Two *ALS2* **deletions in trans in Proband 2. A.** Visualization of proband and parent reads in IGV indicate two overlapping deletions in *ALS2*; a smaller maternal deletion (pink bar) and a larger paternal deletion (blue bar/arrow). Alignment of the proband's assembled maternal (B) or paternal contig (C) versus the reference genome support the two deletions (red dashed lines).

178

179 Proband 3 is a male with a strong X-linked family history of ID (Figure 3A). srES and srGS 180 were both negative, although in srES, two neighboring SNVs were called, and manually curated, 181 in the 3' UTR of HCFC1 (MIM: 300019). While srGS resulted in no calls in this region, visualization 182 of reads in IGV suggested an insertion of unknown length and consequence (Figure 3C). Variation 183 (mostly missense and proposed regulatory variation) in HCFC1 has been associated with X-linked 184 recessive Methylmalonic aciduria and homocysteinemia, cblX type (MIM: 309541). However, 185 most affected individuals present with severely delayed psychomotor development, seizures, and 186 methylmalonic aciduria. Proband 3's family reported neither of the latter two features. Given the 187 uncertainties in the identity, structure and consequence of the variants in both srES and srGS and 188 the lack of clear phenotypic relevance for the gene, these variant calls were curated but not

189 originally considered to be good candidates for clinical relevance. HiFi sequencing identified a 190 4,902 bp mobile element insertion (MEI) in the 3' UTR of HCFC1 (chrX:153948602 ins4902), 191 consisting of both SVA and L1 sequence; this variant was likely inherited from a heterozygous 192 indicated srGS at breakpoints carrier mother, by reads the as



193

Figure 3. Proband 3 has a 4 kb insertion in the 3' UTR of HCFC1. A. The proband's family has a history of X-linked intellectual disability, as the proband (not shown) and two other male relatives (gray squares) are affected. B. Model of the relative length of the insertion in the 3' UTR. C. The insertion is likely inherited from a heterozygous carrier mother, as indicated by srGS reads.

194 (Figure 3C). While this insertion does not affect protein-coding sequence, it is predicted to 195 increase the length of the 3' UTR by 3.75x (from ~1800 nt to about ~6800 nt). We subsequently 196 performed 3'-end RNA-seg on blood from both the proband and his father, generating ~8x10⁶ 197 reads for each sample (see Methods). HCFC1 shows the greatest expression decrease in the 198 proband relative to his father, an ~8.8-fold reduction, among all genes with at least 10 counts in 199 each sample (Supplemental Figure S1). While these results are consistent with the hypothesis 200 that the insertion has a large effect on HCFC1 expression and potential activity, they are not 201 definitive. Further, expression or segregation analyses in additional family members could not be 202 assessed. Given the uncertainty of the molecular consequence, the differences in phenotypic 203 features, and the lack of additional segregation data, we classified this as a VUS, with a case-204 level designation of Uncertain.

205 Proband 4 has a complex tandem *de novo* duplication affecting 16p13.2 206 (NC 000016.9:g.(8742452 9220783)ins[(8742452 8879961) (8879962 9000189)x2 (900019 207 0 9220783)], Table 2, Supplemental Figure S2). Overlapping duplications have been reported in 208 gnomAD but are rare (Lek et al. 2016). One individual in Decipher (Patient: 251349) has also 209 been reported with a very similar duplication of uncertain consequence (Deciphering 210 Developmental Disorders 2015). These duplications span seven genes, three of which are 211 associated with disease: ABAT, PMM2, and USP7. The first (ABAT) is intersected by a duplication 212 breakpoint, but all other breakpoints lie within intergenic regions. USP7 is the only gene 213 associated with autosomal dominant disease (Hao-Fountain Syndrome, MIM:616863), but this 214 gene is expected to have a copy number of four in this proband, while LOF is generally the 215 mechanism associated with disease (Hao et al. 2015). Some general features of Hao-Fountain 216 Syndrome overlap this proband, but it is not a strong phenotypic fit. The proband is reported to 217 have moderate ID, seizures, microcephaly, and facial dysmorphisms. Proband 4 first had a trio 218 srES and no variants were returned, and this duplication was not called. Trio IrGS identified the 219 order, orientation, and copy number of segments of these tandem duplications. We have 220 classified this variant as a VUS, with a case-level designation of Uncertain. Note that this variant 221 is pending orthogonal validation. Proband 4 was one of the two individuals who only previously 222 had srES rather than srGS, and this duplication was not easily visualized in srES data.

223

224 IrGS-informed SNV/Indels

Improved variant calling in repeat regions is also a benefit of IrGS (Nurk et al. 2022). In addition to analysis of SNVs and SVs in our standard pipeline, we assessed variant calls in 66 tandem repeat expansion (TRE) regions, including both known disease-associated and candidate disease-associated loci (Supplemental Table S4). We intersected TRE regions of interest with pbsv-called variants in each individual and compared these calls to known pathogenic expansion sizes from the literature. We identified several large heterozygous insertions in repeat regions

that, while longer than the expected pathogenicity threshold, were predicted after manual curation
to be benign based on their sequence content (Nakamura et al. 2020, Supplemental Figure S3A).
We also identified two large heterozygous insertions in *RFC1* (MIM: 102579), one of which is
benign based on sequence content and one of which is expected to be a pathogenic insertion.
However, *RFC1*-associated disease (CANVAS, MIM: 614575) is caused by biallelic expansions,
which we did not observe (Supplemental Figure S3B), suggesting this proband is merely a
heterozygous carrier.

238 In Proband 5, we observed a *de novo* 18-bp alanine tract expansion in *PHOX2B* (MIM: 239 603851, NM 003924.4:c.741 758dup, p.(Ala255 Ala260dup), Table 2, Supplemental Figure 240 S4), associated with Central Hypoventilation Syndrome, with or without Hirschsprung Disease 241 (MIM: 209880). This disorder was clinically suspected, but variation in PHOX2B was missed by 242 initial clinical genetic testing and srGS, which was performed on a PCR+ srGS library. This variant 243 is reported as pathogenic in literature (Amiel et al. 2003), is a strong match to the proband's 244 observed symptoms, and was confirmed independently by additional clinical testing. We have 245 classified this variant as pathogenic, with a case-level classification of Definitive Diagnostic.

246 In proband 6, we identified a 270 bp insertion in AFF3 (MIM:601464, NM 001386135.1:c.-64-281 -64-280insGGC[90], Table 2, Supplemental Figure S5). While missense variants in AFF3 247 248 have been associated with KINSSHIP Syndrome (MIM:619297), an expansion of a CGG-repeat 249 in the promoter of this gene and subsequent hypermethylation of the promoter has recently been 250 reported to be associated with NDDs (Jadhav et al. 2023). The majority of probands in our cohort 251 (77/96) had both alleles matching hg38 in this region. Among the 19 probands harboring non-252 reference alleles, proband 6 had a 270 bp insertion, and the remaining 18 probands had insertions 253 ranging from 24-84 bp in length (8-28 triplet repeat units). Similarly, when comparing to the larger, 254 "set 2" database of HiFi genomes (n=266), only 53/266 individuals harbor a non-reference allele; 255 the longest insertions outside of Proband 6 are 105 bp (35 repeats) and 93 bp (31 repeats), each 256 in different individuals, while the median non-reference insertion is 36 bp (12 repeats). Thus, the

257 270 bp insertion (90 repeat units) in Proband 6 is a clear outlier, being nearly three-fold longer than the second longest insertion (Supplemental Table S4, Supplemental Figure S6). Proband 6 258 259 was sequenced as a neonate and presented with intrauterine growth restriction (IUGR) and 260 hypoplastic left heart (HLH). Jadhav et al. suggest that normal variation ranges to up to ~38 repeat 261 units, with >= 61 repeats being a likely pathogenic threshold; our results are consistent with those 262 observations. Nevertheless, there is a need to further replicate and confirm the spectrum of 263 normal and pathogenic variation in AFF3 repeat lengths. Given this uncertainty and the 264 uncertainty regarding the proband's cognitive development, we have classified this TRE as a 265 VUS, and the case-level classification is Uncertain. Also note that this variant is pending 266 orthogonal validation.

267 A de novo SHANK3 SNV (NM 033517.1:c.3161delT, p.(Leu1054Argfs*10)) was identified 268 by IrGS in proband 7. While two reads in the srGS data support this 1 bp deletion, the variant was 269 not called by our srGS variant calling pipeline (Supplemental Figure S7). LOF variation in 270 SHANK3 (MIM: 606230) is associated with Phelan-McDermid syndrome (MIM: 606232). Features 271 of this syndrome are consistent with the proband's features, and we classified this variant as 272 pathogenic (case-level Definitive Diagnostic). Coverage of this region in short read data does not 273 indicate a systematic coverage deficiency, as mean coverage within 50 bp of this variant in the 274 srGS data for the cohort is 26.1x (n=96), while it is 15.1x for proband 7. Further, this gene is not 275 present in the list of medically relevant genes that tend to be poorly covered by srGS (Wagner et 276 al. 2022), suggesting it may have resulted from a stochastic loss of alternative allele reads in the 277 srGS data. Nevertheless, IrGS has been shown to provide better overall sensitivity and specificity 278 to SNVs and indels in Genome-In-A-Bottle (GIAB) gold-standard datasets compared to srGS 279 (Logsdon et al. 2020; Hiatt et al. 2021) and thus detection failures to variants such as this SHANK3 280 event are more likely in srGS data in general.

281

283

284 Reinterpretation of SNVs

285 The remaining 9 cases that had relevant variation identified following IrGS illustrate the value of 286 reanalysis and/or reinterpretation (Table 2, Supplemental Case Reports). In three cases 287 (Probands 8-11, HNRNPU, CSNK2B, GNB2, MCF2) we identified variation in genes that had 288 additional published support for association of the gene or the variant with disease since the time 289 of the most recent analysis. In another four cases (Probands 12-15, NOTCH3, AFF4, KCNT2, 290 KIF21A, NRXN1) we identified variation in established disease genes that conflicted with the 291 published data regarding molecular mechanisms or expected mode of inheritance. For these 292 cases, the SNVs were also identified by srGS but they were prioritized more effectively following 293 IrGS, particularly after no new P/LP/VUS SVs of interest were observed. We note that in 7/9 294 cases, variants were identified in an unaffected or mildly affected parent, which was somewhat 295 unexpected in these cases due to suspicion of high penetrance (also see Supplemental Case 296 Reports). Lastly, we identified a variant of interest in SCN1A that resulted from a targeted analysis 297 of candidate "poison exon" variants (Proband 16, Felker et al. 2023).

299 Discussion

300 There remains a considerably large fraction of disease suspected to have genetic causes that is 301 refractory to genomic testing, a finding that has been repeatedly shown across many clinical and 302 research projects (e.g., Srivastava et al. 2019; Baxter et al. 2022). Several non-mutually exclusive 303 hypotheses exist to explain these observations. Environmental risk factors, such as teratogenic 304 exposure or infectious disease, may be relevant to some phenotypes. Multigenic contributors are 305 also likely to explain at least some cases. For example, a small but appreciable fraction of "double 306 diagnoses", in which an affected individual is observed to harbor two distinct diseases resulting 307 from highly penetrant variation in two distinct genes, has been observed in clinical genomic 308 studies (e.g. Posey et al. 2017). Notably, such discoveries are typically only made when the 309 variation in both genes is independently amenable to a pathogenicity determination (e.g., would 310 be P/LP regardless of P/LP variation in the other gene), and it is possible if not probable that at 311 least some conditions result from combinations of variants in different genes that are not 312 pathogenic in isolation (Papadimitriou et al. 2019). At the further end of this spectrum is a 313 polygenic accumulation of many risk-factor alleles, which is known to be relevant to many 314 common, complex diseases and which may contribute to some rare conditions, as has been 315 suggested for at least a subset of neurodevelopmental disorders (Niemi et al. 2018).

316 We find it likely that a substantial fraction of unexplained rare disease arises from highly 317 penetrant, monogenic variation that we have not yet been able to precisely identify or confidently 318 interpret. The results from this study are consistent with that hypothesis, with over 15% of 319 probands with previously negative testing being now found to harbor a relevant or potentially 320 relevant genetic variant. Further, these observations are consistent with the general picture of 321 rare disease testing in recent years. With the advent of exome capture and sequencing ~15 years 322 ago (Ng et al. 2010, 2009) and subsequent improvements in cost and efficiency, genome-wide 323 detection of highly penetrant variation has greatly accelerated in recent years (Bamshad et al. 324 2019; Baxter et al. 2022; Hamosh et al. 2022; Boycott et al. 2022). Long-read genome sequencing

325 represents the next phase of that acceleration by facilitating a substantial increase in variant 326 comprehensiveness and accuracy. We note that this improvement derives from both sensitivity 327 and specificity improvements. For example, effectively all the variation we describe in this study 328 as being newly visible within IrGS is, in fact, visible in srGS data, at least at the breakpoint levels. 329 However, being retrospectively visible, once the location and structure of a variant is known to 330 exist, is a much lower bar than the ability to prospectively detect, define, filter, and curate such 331 variation. For example, we describe here a 4.9 kb insertion of SVA and L1 sequence into the 3' 332 UTR of *HCFC1*. In retrospective analysis, the Mobile-Element Locator Tool (MELT, Gardner et 333 al. 2017) detected a 1.2 kb SVA mobile element at this location in srGS. However, this call is 334 incorrect with respect to size and sequence composition and MELT generally produces too many 335 calls in our srGS data to allow for a sustainable level of manual curation (Hiatt et al. 2021). For 336 example, this proband had 1,311 total MELT calls, 203 of which are within 50 bp of a RefSeq 337 exon. Further, this individual call has an unbalanced number of reads supporting the left and right 338 breakpoints for this event (LP=17; RP=1). The low number of reads supporting the right 339 breakpoint and the incorrect length of the insertion appear to be due to the presence of L1 340 sequence at the 3' end of the insertion, compounded with a long polyA sequence (79 nt).

Our results are also consistent with other studies of the benefits of IrGS for discovering 341 342 genetic contributors to disease. In 2021, for example, we showed in a small pilot project that 2 of 343 6 previously srGS-negative probands harbored clinically relevant variation uniquely interpretable 344 by IrGS (Hiatt et al. 2021). Since that time, several other studies have also used IrGS for molecular 345 diagnosis of rare disease. For example, Cohen and colleagues showed increased yield of GS 346 (both IrGS and srGS) in exome-negative cases (Cohen et al. 2022). Unique discoveries for IrGS 347 included detection of novel repeat expansions of STARD7 and a compound heterozygous 348 SNV/deletion that was easier to detect in IrGS. However, the increase in diagnostic yield (~13%) 349 was mainly from SVs detectable by either IrGS or srGS. Other studies have also shown the 350 diagnostic value of IrGS, especially in small, well-phenotyped cohorts or families (Sakamoto et al.

351 2024; Kilich et al. 2024; Audet et al. 2023; Del Gobbo et al. 2023; Fukuda et al. 2023; Miller et al. 352 2021). Our results are similar to these studies at a high-level. However, some important 353 differences are worth noting. One notable difference is that we have shown the value of IrGS in 354 singletons. While srGS data was available for most of the probands' parents, only 10/96 probands 355 had parent IrGS data. Our filtering strategies were sufficient to allow prioritization of proband 356 variants without parental data; further, once flagged for interest, inheritance data could often be 357 assessed by looking at parental srGS reads. Based on this experience, prioritization of proband 358 sequencing with targeted validation in parents is an effective way to increase diagnostic yield with 359 IrGS while reducing IrGS sequencing needs.

360 We have also provided a direct, systematic comparison of IrGS to contemporaneously 361 analyzed srGS in previously negative cases. Our results thus allow for the separation and 362 description of clinically relevant variants that are "new" by virtue of being truly unique to IrGS 363 versus those that are "new" by virtue of reanalysis, and which could be found via IrGS or srGS-364 reanalysis. In that context, we note that the benefits of reanalysis of older srGS data remain 365 considerable. In the results described here, the "new" discoveries in 9 of 16 cases in IrGS were 366 called correctly and interpretable within srGS data. These observations reflect the rapid pace of 367 gene discovery in rare disease (Baxter et al. 2022; Boycott et al. 2022; Hamosh et al. 2022), and 368 are consistent with other studies. For example, we previously showed that the probability of a 369 negative srGS dataset harboring a clinically relevant variant increased from 1% within one year 370 of a previous analysis to ~22% if more than three years have passed since a previous analysis 371 (Hiatt et al. 2018). Several other studies found similar results, with many reanalysis findings being 372 due to recent publications of new gene-disease associations (Liu et al. 2019; Schobers et al. 373 2022; Hartley et al. 2023).

One possible optimal path to maximizing overall yield in previously srGS-negative individuals is to include reanalysis prior to IrGS. However, this reflects a cost/benefit ratio that depends on the cost of the analysis step in relation to the costs of sequencing. As IrGS costs

decrease there may reach a point where the cost of variant analysis alone (which requires both compute resources and manual curation time and thus represents a non-trivial cost) is substantial relative to IrGS costs per se and which might favor a process of simply performing IrGS. Further, IrGS allows analysis of a more complete genomic picture, including both SNVs and larger variant types that are truly not called in srGS data. This can allow more accurate and confident variant prioritization (including SNVs) as evidenced by several of our cases.

383 We note that the results in this study were generated over a period of time with 384 considerable change in IrGS protocols. For example, most probands in this study were sequenced 385 on Sequel IIE machines (n=64) before the Revio (n=32) became available. Given the costs of 386 data production, the 64 Sequel IIE samples were covered at lower-depth (median coverage 387 24.65X) than the 32 Revio-sequenced samples (median coverage 30.09X, Supplemental Figure 388 S8), which may have reduced our sensitivity to variants in some loci in the earlier samples. 389 Further, methylation data were not available in the early period of this study, although methylation 390 calls are now routine and available for the most recent 44 probands, which may also impact 391 diagnostic yield. For example, evaluation of the, at present VUS, AFF3 expansion (Supplemental 392 Figure S5, S6) would benefit from an assessment of methylation levels at this locus, as 393 hypermethylation is likely associated with disease risk (Jadhav et al. 2023). Additionally, some 394 probands harbor methylation alterations that are clinically relevant even in the absence of a 395 pathogenic genetic variant (Aref-Eshghi et al. 2021).

In addition to changes in sequencing, informatic changes have also been considerable over the course of the data generation for this study. While we present and describe a uniform set of variant-calls, assemblies, and annotations (see Methods), analysis of individual samples took place simultaneously with the optimization of variant-calling and annotation pipelines. One particularly relevant change is variant-frequency annotations. While the key strength of IrGS is its ability to see variants that are invisible or poorly detected in srGS, the ability to discriminate genuine highly penetrant variation from the background of benign alleles depends on the ability

403 to annotate and remove alleles that are common in the general population. As the main allele 404 frequency resources are built from srGS data (e.g., Lek et al. 2016), we have limited ability to filter 405 away likely benign alleles among the variants uniquely detected by IrGS. This ability, however, 406 improved as more IrGS datasets were produced over the course of this study (Ebert et al. 2021; 407 Nurk et al. 2022). Projects like the COLORs consortium (https://colorsdb.org/) are likely to improve 408 frequency annotation in the future and continue to improve variant curation efficacy. Accumulating 409 IrGS data from as many samples and studies as possible is critical for the long-term maximization 410 of IrGS benefits.

In sum, rare disease genetics continues to be a rapidly advancing field. With data-sharing (Sobreira et al. 2015; Philippakis et al. 2015) and technology improvement (Wenger et al. 2019), the overall diagnostic yield for individuals with rare disease is increasing at a considerable pace each year. In that context, IrGS is a decisive improvement over srGS, providing substantial gains to variant specificity and sensitivity, especially for complex and repeat-associated variants. We anticipate that the degree of improvement will widen over time, as sequencing and analysis pipelines mature and as IrGS datasets grow.

419 **METHODS**

420 Short-read sequencing and variant calling

421 Probands, their parents, and, when appropriate, affected siblings were enrolled in one of four 422 research studies aimed at identifying genetic causes of rare disease (Bowling et al. 2017; East et 423 al. 2021; Bowling et al. 2022 and Pediatric Genomics (PGEN), unpublished). These studies were 424 monitored by Western IRB and UAB IRB (WIRB 0071, UAB IRB protocols 170303004, 425 300000328, and 130201001). A parent or legal guardian gave consent for the proband, and 426 assent was also obtained from those probands who were capable. In some cases, adult probands 427 who were capable consented to participation in the study. All enrolled individuals consented to 428 publication of de-identified data. Short read exome (srES) or short-read genome sequencing 429 (srGS) was performed as described (Bowling et al. 2022; East et al. 2021; Hiatt et al. 2021; 430 Bowling et al. 2017). Briefly, whole blood genomic DNA was isolated using the QIAsymphony 431 (Qiagen), and sequencing libraries were constructed by the HudsonAlpha Genomic Services Lab 432 or the Clinical Services Laboratory, LLC, using a standard protocol that generally included PCR 433 amplification (86/96). Genomes were sequenced at an approximate mean depth of 30X, with at 434 least 80% of base positions reaching 20X coverage. Exomes were sequenced to a mean depth 435 of 71X. For short read reanalysis, srES and srGS reads were aligned and small variants and 436 CNVs were called with a uniform pipeline to hg38, and SNVs/Indels and CNVs were curated using 437 an in-house software tool, as previously described (Hiatt et al. 2021). Expected sample 438 relatedness was confirmed with Somalier (v. 0.2.10, (Pedersen et al. 2020) and predicted major 439 genetic ancestries were calculated with peddy (v. 0.4.1, Pedersen and Quinlan 2017).

440

441 Long-Read sequencing, variant calling, analysis and de novo assemblies

Long-read sequencing was performed using HiFi (CCS) mode on either a PacBio Sequel II or Revio instrument (Pacific Biosciences of California, Inc.). Libraries were constructed using a SMRTbell Template Prep Kit (V1.0, 2.0 or 3.0) and tightly sized on a SageELF or BluePippin

445 instrument (Sage Science, Beverly, MA, USA). Sequencing was performed using a 2 hour preextension with either 24 or 30 hour movie times. The resulting raw data was processed using 446 447 either the CCS3.4 or CCS4 algorithm, as the latter was released during the course of the study. 448 Comparison of the number of high-quality indel events in a read versus the number of passes 449 confirmed that these algorithms produced comparable results. Probands were sequenced on 2-3 450 Sequel II or one Revio SMRT cell. Top off sequencing was performed if the sequencing did not 451 meet the desired coverage (>20X). This resulted in an average estimated HiFi read depth of 26.1X 452 (range 16.7-41) of raw, unaligned sequence data for probands, For 10 families, parents were also 453 sequenced on 2-3 Sequel II SMRT cells, with an average estimated depth of 21.6x (range 14-28) 454 of raw, unaligned sequence data for parents. Aligned sequencing metrics are shown in 455 Supplemental Tables S1 and S2. HiFi reads were aligned to the were aligned to the hg38 no-alt 456 analysis set

457 (https://ftp.ncbi.nlm.nih.gov/genomes/all/GCA/000/001/405/GCA_000001405.15_GRCh38/seqs

458 <u>for alignment pipelines.ucsc ids/GCA 000001405.15 GRCh38 no alt analysis set.fna.gz</u>) 459 using pbmm2 (v. 1.10.0). SNVs and small indels,were called with DeepVariant (v. 1.5.0) and used 460 to haplotag the aligned reads with whatshap (v. 1.7). Structural variants were called using pbsv 461 v2.9.0 (https://github.com/PacificBiosciences/pbsv). For the 10 cases with parent IrGS, candidate 462 de novo SVs required a proband genotype of 0/1 and parent genotypes of 0/0, with \geq 6 alternate 463 reads in the proband and 0 alternate reads, and \geq 5 reference reads in the parents.

464

De novo assemblies were generated for all probands using hifiasm (v. 0.15.2 (r334 or v.0.16.1r375, Cheng et al. 2021). Hifiasm was used to create two assemblies. First, the default parameters were used, followed by two rounds of Racon (v1.4.10) polishing of contigs. For cases with parent GS data, trio-binned assemblies were built using kmers (srGS). The kmers were generated using yak (v0.1) using the suggested parameters for running a hifiasm trio assembly (kmer size=31 and Bloom filter size of 2**37). Maternal and paternal contigs went through two rounds of Racon

471 (v1.4.10) polishing. Individual parent assemblies were also built with hifiasm (v0.15.2) using
472 default parameters. The resulting contigs went through two rounds of Racon (v1.4.10) polishing.
473

474 Coordinates of breakpoints were defined by a combination of assembly-assembly alignments
475 using minimap2 (Li 2018) (followed by use of bedtools bamToBed), visual inspection of CCS read
476 alignments, and BLAT. Dot plots illustrating sequence differences were created using Gepard
477 (Krumsiek et al. 2007).

478

479 Structural Variant Merging and Filtering

Overall structural variant counts in Supplemental Table S1 were generated from the proband pbsv
VCFs using bcftools (v1.15.1) and awk (e.g., bcftools filter -i 'SVTYPE=="DEL" <input.vcf> |
{a[i++]=\$1; sum+=\$1} END{asort(a); min=a[1]; max=a[i]; if(i%2==1) median=a[int(i/2)+1]; else
median=(a[i/2]+a[i/2+1])/2; mean=sum/i; print mean, median, min, max;).

485 An internal allele frequency callset was constructed and periodically updated using all available 486 internally sequenced HiFi pbsv variant calls and pbsv calls generated from public HiFi sequencing 487 data (n=266 at the end of this analysis). Samples included a majority of participants from this 488 cohort and our previous NDD pilot cohort (Hiatt et al. 2021, 120/266); samples from HudsonAlpha 489 non-NDD projects (35/266); HudsonAlpha-sequenced data from HG001, HG003, HG004, HG006, 490 and HG007 (5/266); HG00514, HG00731, HG00732, NA19240 from HGSVC2 (Ebert et al. 2021) 491 (4/266); CHM13 (1/266)(Nurk et al. 2022), 492 (https://www.ncbi.nlm.nih.gov/sra/?term=SRX789768*+CHM13)) the HPRC Year 1 and 493 HPRC PLUS Year 2 releases (101/266)(Ebert et al. 2021). Pbsv calls were merged naively using 494 bcftools merge (v. 1.15.1), i.e., merging only variants that were identical in terms of location, 495 reference sequence, and alternate sequence. The internal pbsv allele frequency callset included 496 affected probands as well as parent/child trios.

497

498 A more robustly merged cohort callset (n=96) was constructed using Jasmine, which allows for 499 merging of similar structural variants that may have non-identical representation in terms of 500 genomic position or variant sequence via spanning a structural variant proximity graph. Jasmine 501 was run with options --centroid merging --min overlap=0.65 --min sequence id=0.75 --502 output genotypes to create the merged callset. This cohort callset was then annotated with five 503 sets of structural variant frequency annotation. Cohort allele frequencies were generated from the 504 merged set with bcftools +fill-tags (set 1, n=96). A second Jasmine merge was used to combine 505 the cohort callset allele count with additional allele frequency resources: the HudsonAlpha internal 506 pbsv callset (described above) (set 2, n=266); gnomAD structural variants (Collins et al. 2020, 507 v4.0, https://gnomad.broadinstitute.org/news/2023-11-v4-structural-variants) (set 3, n=63,046); 508 HGSVC2 structural variants (Ebert al. 2021) et 509 https://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data collections/HGSVC2/release/v2.0/integrated ca 510 llset/variants freeze4 sv insdel alt.vcf.gz) (set 4, n=18); pbsv calls for individuals from the 511 Human Pangenome Reference Consortium and Genome in Bottle (PacBio; а 512 https://github.com/PacificBiosciences/svpack/raw/main/resources/HPRC GIAB.GRCh38.pbsv.v 513 cf.gz) (set 5, n=103). The second Jasmine merge was run with the prior settings but without the -514 -output genotypes option and records without genotypes were discarded. A custom python script 515 was used to transfer allele frequency annotations from the annotation source VCFs to the merged 516 VCF based on unique variant identifiers (which were created for each allele frequency resource 517 as needed) and the IDLIST record from Jasmine. The annotated callset was split into individual 518 VCFs with bcftools (bcftools view -I -s <id>) which were filtered with bcftools to generate the 519 counts in Supplemental Table S2. The "rare" filter described in Supplemental Table S3 was 520 defined as excluding variants with any of the following: within-cohort allele count > 3, in-house 521 allele count > 3, gnomAD maximum population allele frequency (POPMAX AF) >= 1%, 522 HPRC GIAB allele frequency >=1%, or HGSVC2 allele frequency >= 1%. The "proband-

523 exclusive" filter described in Supplemental Table S3 was defined as excluding variants with any 524 of the following: within-cohort allele count > 1, in-house allele count > 2, gnomAD allele count > 525 0, HPRC GIAB allele count > 0, or HGSVC2 allele count > 0. The in-house allele count cutoff 526 was set at 2 in order to account for the fact that some parental samples were included in the inhouse frequency database. Exon regions were defined as RefSeq exons +/- 50bp (calculated 527 528 from bedtools slop). Variant filtering and counting was performed with bcftools view and 529 command-line tools, e.g., bcftools view -R refseq exons plus50bp.bed.gz -e 'AC>3 | 530 inhouse pbsv AC >3 | gnomad4 POPMAX AF >= 0.01 | hgsvc2 AF >= 0.01 | 531 hprc_giab_pbsv_AF >= 0.01' -H <input file> | wc -l for the rare filter and bcftools view -R refseq exons plus50bp.bed.gz -e 'AC>1 | inhouse pbsv AC>2 | gnomad4 AC>0 | 532 533 hgsvc2 AC>0 | hprc giab pbsv AC>0' -H <input file> | wc -I for the exclusive filter.

534

535 Structural Variant Annotation and Curation

536 For individual case structural variant analysis, a frequency-filtered subset of the proband's pbsv 537 calls was generated using bcftools annotate and bcftools filter, requiring that calls be located 538 within +/- 50bp of a RefSeq exon and have an allele count of < 4 in the HudsonAlpha internal 539 allele frequency dataset (described above). Each call was visualized using a custom pipeline to 540 automatically generate IGV screenshots (Robinson et al. 2011). Additionally, these filtered pbsv 541 variants were annotated, prioritized, and visualized with SvAnna (v1.0.4, annotations v.2204 or 542 v.230, Danis et al. 2022) based on manually curated HPO terms for each case.

543

544 Variant interpretation and orthogonal confirmation

545 Variant interpretation was performed using ACMG and ClinGen (Richards et al. 2015; Riggs et 546 al. 2020). Variants of interest were either clinically confirmed by the HudsonAlpha Clinical 547 Services Lab, were confirmed within a research lab, and/or were supported by short-read 548 orthogonal data, except where noted in the text (Table 2).

549

550 Sequencing Metrics

551 Sequencing metrics were generated from the aligned BAMs using the Sentieon implementations 552 of Picard sequencing metrics (Kendig et al. 2019). Sentieon algorithms QualityYield, GCBias, 553 AlignmentStat were run with default settings. Sentieon WgsMetricsAlgo was run with settings --554 include unpaired true true --min map qual 0 --min base qual 0 --coverage cap 5000. Further 555 coverage metrics were generated with cramino using the --phased option. Supplemental Table 556 S5 maps each tool or command and output field name to the corresponding entry in Supplemental 557 Tables S1 and S2. SNV and indel counts and ratios were calculated with rtg vcfstats 558 (https://github.com/RealTimeGenomics/rtg-tools). Summary statistics and graphs were calculated 559 with R (v4.3.1), RStudio (v2023.9.1 build 494), and ggplot2 (v3.4.3). Coverage across regions of 560 interest, such as SHANK3 was calculated using samtools bedcov with default parameters.

561

562 Repeat region detection and analysis

563 We curated a BED file of disease-associated low-complexity repeat regions in 66 genes from 564 previous studies (Hiatt et al. 2021; Cohen et al. 2022 and references therein). Variant calls from 565 pbsv were extracted from these regions +/- 30bp (Supplemental Table S4). Reads were also 566 visualized using the Integrated Genomics Viewer (IGV). Coverage across low complexity repeat 567 regions was calculated using samtools bedcov with default parameters. A coverage of at least 8x 568 across the low-complexity region was required for inclusion in Supplemental Table S4 and 569 Supplemental Figure S6. We also used TRGT (Dolzhenko et al. 2024) and companion tool TRVZ 570 for visualization of a subset of calls including those for display in Figure S3. TRGT was fed an 571 hg38 reference genome FASTA, BED catalog of tandem repeats, and a sample's BAM to 572 generate a VCF containing genotypes for each tandem repeat from the provided catalog in the given sample and a BAM containing only reads that span the repeat sequences. Output VCFs 573

and BAMs were sorted, indexed, and fed into TRVZ with the same hg38 reference FASTA and
BED catalog of tandem repeats to generate pileup plots for any desired variants.

576

577 3' mRNA-seq

578 Total RNA was isolated from blood samples in PAXgene RNA tubes (PreAnalytiX #762165) 579 according to the manufacturer's instructions and stored short-term at -20°C. RNA was isolated 580 using the PAX gene Blood RNA Kit (Qiagen #762164) according to the manufacturer's 581 instructions. Isolated RNA was quantified by the Qubit RNA HS Assay Kit (Thermo Q32855). 425 582 ng of RNA was used as input for the QuantSeq 3' mRNA-Seq Library Prep Kit FWD for Illumina 583 and UMI Second Strand Synthesis Module for QuantSeg FWD (Illumina, Read 1) from Lexogen 584 (015.96 and 081.96, respectively). Libraries were quantified using the Qubit DNA HS Assay Kit 585 (Thermo Q32854) and visualized with the BioAnalyzer High Sensitivity DNA Analysis kit (Agilent 586 5067-4626) and 2100 BioAnalyzer Instrument (Agilent). Sequencing was carried out using 587 Illumina NextSeq 75 bp single-end. UMIs were first extracted from the reads with UMI-tools extract 588 with regex. Reads were then trimmed with bbduk and aligned to hg38-GENCODEv42 using STAR 589 with the Lexogen recommended parameters for QuantSeq. Bams were deduplicated by UMI and 590 mapping coordinates using UMI-tools dedup. Count tables were generated using htseq-count with 591 the intersection-nonempty method.

592

593 DATA ACCESS

594 For participants who consented to controlled-access sharing, the IrGS data generated in this study 595 will be submitted to dbGAP and/orAnVIL under accession number phs003537.v1 596 (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003537.v1).

597 srGS data for participants who consented to controlled-access sharing in NIH-funded studies are 598 available via dbGAP and/or AnVIL (CSER1: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-

bin/study.cgi?study_id=phs001089.v3.p1, dbGaP accession phs001089; SouthSeq:
https://anvilproject.org/data/studies/phs002307, dbGaP accession phs002307).

601

602

603 COMPETING INTEREST STATEMENT

604 The authors declare no competing interests.

605

606 ACKNOWLEDGMENTS

607 We thank the families who have contributed to our studies and our collaborating physicians and 608 clinical staff for recruitment and enrollment for these research studies. Some reagents were 609 provided by PacBio as part of an early-access testing program. The CSER1 project was 610 supported by a grant from the US National Human Genome Research Institute (NHGRI; 611 UM1HG007301). The SouthSeg project (U01HG007301) was supported by the Clinical 612 Sequencing Evidence-Generating Research (CSER2) consortium, which is funded by the 613 National Human Genome Research Institute with co-funding from the National Institute on 614 Minority Health and Health Disparities and the National Cancer Institute. The Alabama Genomic 615 Health Initiative is an Alabama-State earmarked project (F170303004) through the University of 616 Alabama in Birmingham. The PGEN cohort was funded by the Alabama Pediatric Genomics 617 Initiative. IrGS of some samples was supported by a Research Grant from the Muscular Dystrophy 618 Association (MDA 963255).

- 619
- 620

621 **REFERENCES**

- Amiel J, Laudier B, Attié-Bitach T, Trang H, De Pontual L, Gener B, Trochet D, Etchevers H,
 Ray P, Simonneau M, et al. 2003. Polyalanine expansion and frameshift mutations of the
 paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome. *Nat Genet* 33: 459–461. https://pubmed.ncbi.nlm.nih.gov/12640453/ (Accessed February 5,
 2024).
- Aref-Eshghi E, Kerkhof J, Pedro VP, France G DI, Barat-Houari M, Ruiz-Pallares N, Andrau JC,
 Lacombe D, Van-Gils J, Fergelot P, et al. 2021. Evaluation of DNA Methylation
- 629 Episignatures for Diagnosis and Phenotype Correlations in 42 Mendelian
- 630 Neurodevelopmental Disorders. *Am J Hum Genet* **108**: 1161–1163.
- 631 https://pubmed.ncbi.nlm.nih.gov/34087165/ (Accessed February 27, 2024).
- Audet S, Triassi V, Gelinas M, Legault-Cadieux N, Ferraro V, Duquette A, Tetreault M. 2023.
 Integration of multi-omics technologies for molecular diagnosis in ataxia patients. *Front Genet* 14: 1304711. http://www.ncbi.nlm.nih.gov/pubmed/38239855 (Accessed February
 13, 2024).
- 636 Bamshad MJ, Nickerson DA, Chong JX. 2019. Mendelian Gene Discovery: Fast and Furious 637 with No End in Sight. *Am J Hum Genet* **105**: 448–455.
- 638 https://pubmed.ncbi.nlm.nih.gov/31491408/ (Accessed July 19, 2022).
- Baxter SM, Posey JE, Lake NJ, Sobreira N, Chong JX, Buyske S, Blue EE, Chadwick LH,
 Coban-Akdemir ZH, Doheny KF, et al. 2022. Centers for Mendelian Genomics: A decade
 of facilitating gene discovery. *Genet Med* 24: 784–797.
- 642 https://pubmed.ncbi.nlm.nih.gov/35148959/ (Accessed April 16, 2023).
- 643 Bowling KM, Thompson ML, Amaral MD, Finnila CR, Hiatt SM, Engel KL, Cochran JN, Brothers 644 KB, East KM, Gray DE, et al. 2017. Genomic diagnosis for children with intellectual
- 645 disability and/or developmental delay. *Genome Med* **9**: 43.
- 646 http://www.ncbi.nlm.nih.gov/pubmed/28554332.
- Bowling KM, Thompson ML, Finnila CR, Hiatt SM, Latner DR, Amaral MD, Lawlor JMJ, East
 KM, Cochran ME, Greve V, et al. 2022. Genome sequencing as a first-line diagnostic test
 for hospitalized infants. *Genet Med* 24: 851–861.
- 650 https://pubmed.ncbi.nlm.nih.gov/34930662/ (Accessed May 29, 2023).
- 651 Boycott KM, Azzariti DR, Hamosh A, Rehm HL. 2022. Seven years since the launch of the
- Matchmaker Exchange: The evolution of genomic matchmaking. *Hum Mutat* 43: 659–667.
 https://pubmed.ncbi.nlm.nih.gov/35537081/ (Accessed July 19, 2022).
- Cheng H, Concepcion GT, Feng X, Zhang H, Li H. 2021. Haplotype-resolved de novo assembly
 using phased assembly graphs with hifiasm. *Nat Methods* 18: 170–175.
- 656 https://pubmed.ncbi.nlm.nih.gov/33526886/ (Accessed February 6, 2024).
- Cohen ASA, Farrow EG, Abdelmoity AT, Alaimo JT, Amudhavalli SM, Anderson JT, Bansal L,
 Bartik L, Baybayan P, Belden B, et al. 2022. Genomic answers for children: Dynamic
- analyses of >1000 pediatric rare disease genomes. *Genetics in Medicine* 24: 1336–1348.
 https://pubmed.ncbi.nlm.nih.gov/35305867/ (Accessed August 24, 2022).
- 661 Collins RL, Brand H, Karczewski KJ, Zhao X, Alföldi J, Francioli LC, Khera A V., Lowther C,
- 662 Gauthier LD, Wang H, et al. 2020. A structural variation reference for medical and

663 population genetics. Nature 581: 444–451. https://pubmed.ncbi.nlm.nih.gov/32461652/ 664 (Accessed February 15, 2024). 665 Danis D, Jacobsen JOB, Balachandran P, Zhu Q, Yilmaz F, Reese J, Haimel M, Lyon GJ, 666 Helbig I. Mungall CJ. et al. 2022. SvAnna: efficient and accurate pathogenicity prediction of 667 coding and regulatory structural variants in long-read genome sequencing. Genome Med 668 14. https://pubmed.ncbi.nlm.nih.gov/35484572/ (Accessed February 12, 2024). 669 Deciphering Developmental Disorders S. 2015. Large-scale discovery of novel genetic causes 670 of developmental disorders. Nature 519: 223-228. 671 https://www.ncbi.nlm.nih.gov/pubmed/25533962. 672 Del Gobbo GF, Wang X, Couse M, Mackay L, Goldsmith C, Marshall AE, Liang Y, Lambert C, 673 Zhang S, Dhillon H, et al. 2023. Long-read genome seguencing reveals a novel intronic 674 retroelement insertion in NR5A1 associated with 46,XY differences of sexual development. 675 Am J Med Genet A. http://www.ncbi.nlm.nih.gov/pubmed/38131126 (Accessed February 676 13. 2024). 677 Dolzhenko E, English A, Dashnow H, De Sena Brandine G, Mokveld T, Rowell WJ, Karniski C, 678 Kronenberg Z, Danzi MC, Cheung WA, et al. 2024. Characterization and visualization of 679 tandem repeats at genome scale. Nature Biotechnology 2024 1–9. 680 https://www.nature.com/articles/s41587-023-02057-3 (Accessed February 15, 2024). 681 East KM, Kelley W V., Cannon A, Cochran ME, Moss IP, May T, Nakano-Okuno M, Sodeke SO, 682 Edberg JC, Cimino JJ, et al. 2021. A state-based approach to genomics for rare disease 683 and population screening. Genet Med 23: 777-781. https://pubmed.ncbi.nlm.nih.gov/33244164/ (Accessed July 26, 2022). 684 685 Ebert P, Audano PA, Zhu Q, Rodriguez-Martin B, Porubsky D, Bonder MJ, Sulovari A, Ebler J, 686 Zhou W, Mari RS, et al. 2021. Haplotype-resolved diverse human genomes and integrated 687 analysis of structural variation. Science (1979) 372. 688 Felker SA, Lawlor JMJ, Hiatt SM, Thompson ML, Latner DR, Finnila CR, Bowling KM, 689 Bonnstetter ZT, Bonini KE, Kelly NR, et al. 2023. Poison exon annotations improve the 690 vield of clinically relevant variants in genomic diagnostic testing. Genet Med 100884. 691 https://pubmed.ncbi.nlm.nih.gov/37161864/ (Accessed May 29, 2023). 692 Fukuda H, Mizuguchi T, Doi H, Kameyama S, Kunii M, Joki H, Takahashi T, Komiya H, Sasaki 693 M, Miyaji Y, et al. 2023. Long-read sequencing revealing intragenic deletions in exome-694 negative spastic paraplegias. J Hum Genet 68: 689-697. 695 Gardner EJ, Lam VK, Harris DN, Chuang NT, Scott EC, Stephen Pittard W, Mills RE, Devine 696 SE. 2017. The mobile element locator tool (MELT): Population-scale mobile element 697 discovery and biology. Genome Res 27: 1916-1929. 698 Hamosh A, Wohler E, Martin R, Griffith S, Rodrigues E da S, Antonescu C, Doheny KF, Valle D, 699 Sobreira N. 2022. The impact of GeneMatcher on international data sharing and 700 collaboration. Hum Mutat 43: 668–673. https://pubmed.ncbi.nlm.nih.gov/35170833/ 701 (Accessed July 19, 2022). 702 Hao YH, Fountain MD, Fon Tacer K, Xia F, Bi W, Kang SHL, Patel A, Rosenfeld JA, Le Caignec 703 C, Isidor B, et al. 2015. USP7 Acts as a Molecular Rheostat to Promote WASH-Dependent 704 Endosomal Protein Recycling and Is Mutated in a Human Neurodevelopmental Disorder. 705 Mol Cell 59: 956–969. https://pubmed.ncbi.nlm.nih.gov/26365382/ (Accessed February 11, 706 2024).

707 Hartley T. Soubry É. Acker M. Osmond M. Couse M. Gillespie MK. Ito Y. Marshall AE. Lemire 708 G, Huang L, et al. 2023. Bridging clinical care and research in Ontario, Canada: 709 Maximizing diagnoses from reanalysis of clinical exome sequencing data. Clin Genet 103: 710 288-300. 711 Hiatt SM, Amaral MD, Bowling KM, Finnila CR, Thompson ML, Gray DE, Lawlor JMJ, Cochran 712 JN, Bebin EM, Brothers KB, et al. 2018. Systematic reanalysis of genomic data improves 713 quality of variant interpretation. Clin Genet 94. 714 Hiatt SM, Lawlor JMJ, Handley LH, Ramaker RC, Rogers BB, Partridge EC, Boston LB, 715 Williams M, Plott CB, Jenkins J, et al. 2021, Long-read genome sequencing for the 716 molecular diagnosis of neurodevelopmental disorders. HGG Adv 2: 100023. 717 http://www.ncbi.nlm.nih.gov/pubmed/33937879 (Accessed June 9, 2021). 718 Jadhav B, Garg P, van Vugt JJ, Ibanez K, Gagliardi D, Lee W, Shadrina M, Mokveld T, 719 Dolzhenko E, Martin-Trujillo A, et al. 2023. A phenome-wide association study of 720 methylated GC-rich repeats identifies a GCC repeat expansion in AFF3 as a significant 721 cause of intellectual disability. medRxiv. https://pubmed.ncbi.nlm.nih.gov/37205357/ 722 (Accessed February 6, 2024). 723 Juven A, Nambot S, Piton A, Jean-Marcais N, Masurel A, Callier P, Marle N, Mosca-Boidron AL, 724 Kuentz P, Philippe C, et al. 2020. Primrose syndrome: a phenotypic comparison of patients with a ZBTB20 missense variant versus a 3q13.31 microdeletion including ZBTB20. Eur J 725 726 Hum Genet 28: 1044–1055. https://pubmed.ncbi.nlm.nih.gov/32071410/ (Accessed 727 February 15, 2024). 728 Kendig KI, Baheti S, Bockol MA, Drucker TM, Hart SN, Heldenbrand JR, Hernaez M, Hudson 729 ME, Kalmbach MT, Klee EW, et al. 2019. Sentieon DNASeg Variant Calling Workflow 730 Demonstrates Strong Computational Performance and Accuracy. Front Genet 10. 731 https://pubmed.ncbi.nlm.nih.gov/31481971/ (Accessed February 15, 2024). 732 Kilich G, Hassey K, Behrens EM, Falk M, Vanderver A, Rader DJ, Cahill PJ, Raper A, Zhang Z, 733 Westerfer D, et al. 2024. Kagami Ogata syndrome: a small deletion refines critical region 734 for imprinting. NPJ Genom Med 9: 5. http://www.ncbi.nlm.nih.gov/pubmed/38212313 735 (Accessed February 13, 2024). 736 Kirsche M, Prabhu G, Sherman R, Ni B, Battle A, Aganezov S, Schatz MC. 2023. Jasmine and 737 Iris: population-scale structural variant comparison and analysis. Nat Methods 20: 408-738 417. https://pubmed.ncbi.nlm.nih.gov/36658279/ (Accessed February 15, 2024). 739 Krumsiek J, Arnold R, Rattei T. 2007. Gepard: a rapid and sensitive tool for creating dotplots on 740 genome scale. 23: 1026–1028. http://mips.gsf.de/services/analysis/gepard (Accessed May 741 18, 2020). 742 Lek M, Karczewski KJ, Minikel E V, Samocha KE, Banks E, Fennell T, O'Donnell-Luria AH, 743 Ware JS, Hill AJ, Cummings BB, et al. 2016. Analysis of protein-coding genetic variation in 744 60,706 humans. Nature 536: 285–291. https://www.ncbi.nlm.nih.gov/pubmed/27535533. 745 Li H. 2018. Minimap2: Pairwise alignment for nucleotide sequences. Bioinformatics 34: 3094-746 3100. https://github.com/ruanjue/smartdenovo; (Accessed September 7, 2020). 747 Liu P, Meng L, Normand EA, Xia F, Song X, Ghazi A, Rosenfeld J, Magoulas PL, Braxton A, 748 Ward P, et al. 2019. Reanalysis of Clinical Exome Sequencing Data. New England Journal 749 of Medicine 380: 2478-2480.

750 Logsdon GA. Vollger MR. Eichler EE. 2020. Long-read human genome sequencing and its 751 applications. Nat Rev Genet 21: 597-614. https://www.nature.com/articles/s41576-020-752 0236-x (Accessed November 4, 2020). 753 Mahmoud M, Huang Y, Garimella K, Audano PA, Wan W, Prasad N, Handsaker RE, Hall S, 754 Pionzio A, Schatz MC, et al. 2024. Utility of long-read sequencing for All of Us. Nat 755 Commun 15: 837. https://pubmed.ncbi.nlm.nih.gov/38281971/ (Accessed February 5, 756 2024). 757 Miller DE, Sulovari A, Wang T, Loucks H, Hoekzema K, Munson KM, Lewis AP, Fuerte EPA, 758 Paschal CR, Walsh T, et al. 2021, Targeted long-read seguencing identifies missing 759 disease-causing variation. Am J Hum Genet 108: 1436–1449. 760 https://pubmed.ncbi.nlm.nih.gov/34216551/ (Accessed February 13, 2024). 761 Nakamura H, Doi H, Mitsuhashi S, Miyatake S, Katoh K, Frith MC, Asano T, Kudo Y, Ikeda T, 762 Kubota S, et al. 2020. Long-read sequencing identifies the pathogenic nucleotide repeat 763 expansion in RFC1 in a Japanese case of CANVAS. J Hum Genet 65: 475-480. 764 https://www.nature.com/articles/s10038-020-0733-y (Accessed June 27, 2021). 765 Ng SB, Buckingham KJ, Lee C, Bigham AW, Tabor HK, Dent KM, Huff CD, Shannon PT, Jabs 766 EW, Nickerson DA, et al. 2010. Exome sequencing identifies the cause of a mendelian 767 disorder. Nat Genet 42: 30-35. https://pubmed.ncbi.nlm.nih.gov/19915526/ (Accessed 768 February 27, 2024). 769 Ng SB, Turner EH, Robertson PD, Flygare SD, Bigham AW, Lee C, Shaffer T, Wong M, 770 Bhattacharjee A, Eichler EE, et al. 2009. Targeted capture and massively parallel 771 sequencing of 12 human exomes. Nature 461: 272-276. 772 https://pubmed.ncbi.nlm.nih.gov/19684571/ (Accessed February 13, 2024). 773 Niemi MEK, Martin HC, Rice DL, Gallone G, Gordon S, Kelemen M, McAloney K, McRae J, 774 Radford EJ, Yu S, et al. 2018. Common genetic variants contribute to risk of rare severe 775 neurodevelopmental disorders. Nature 562: 268-271. 776 https://pubmed.ncbi.nlm.nih.gov/30258228/ (Accessed February 11, 2024). 777 Nurk S, Koren S, Rhie A, Rautiainen M, Bzikadze A V., Mikheenko A, Vollger MR, Altemose N, 778 Uralsky L. Gershman A. et al. 2022. The complete sequence of a human genome. Science 779 376: 44-53. https://pubmed.ncbi.nlm.nih.gov/35357919/ (Accessed January 28, 2024). 780 Papadimitriou S, Gazzo A, Versbraegen N, Nachtegael C, Aerts J, Moreau Y, Van Dooren S, 781 Nowé A, Smits G, Lenaerts T. 2019. Predicting disease-causing variant combinations. Proc. 782 Natl Acad Sci U S A 116: 11878–11887. https://pubmed.ncbi.nlm.nih.gov/31127050/ 783 (Accessed February 14, 2024). 784 Pedersen BS, Bhetariya PJ, Brown J, Kravitz SN, Marth G, Jensen RL, Bronner MP, Underhill 785 HR, Quinlan AR. 2020. Somalier: rapid relatedness estimation for cancer and germline 786 studies using efficient genome sketches. Genome Med 12. 787 https://pubmed.ncbi.nlm.nih.gov/32664994/ (Accessed February 15, 2024). 788 Pedersen BS, Quinlan AR. 2017. Who's Who? Detecting and Resolving Sample Anomalies in 789 Human DNA Sequencing Studies with Peddy. Am J Hum Genet 100: 406–413. 790 https://pubmed.ncbi.nlm.nih.gov/28190455/ (Accessed February 15, 2024). 791 Philippakis AA, Azzariti DR, Beltran S, Brookes AJ, Brownstein CA, Brudno M, Brunner HG, 792 Buske OJ, Carey K, Doll C, et al. 2015. The Matchmaker Exchange: A Platform for Rare

- 793 Disease Gene Discovery. *Hum Mutat* **36**: 915–921.
- 794 http://doi.wiley.com/10.1002/humu.22858 (Accessed November 25, 2018).
- Poplin R, Chang PC, Alexander D, Schwartz S, Colthurst T, Ku A, Newburger D, Dijamco J,
 Nguyen N, Afshar PT, et al. 2018. A universal snp and small-indel variant caller using deep
 neural networks. *Nat Biotechnol* **36**: 983.
- Posey JE, Harel T, Liu P, Rosenfeld JA, James RA, Coban Akdemir ZH, Walkiewicz M, Bi W,
 Xiao R, Ding Y, et al. 2017. Resolution of Disease Phenotypes Resulting from Multilocus
 Genomic Variation. *N Engl J Med* **376**: 21–31. https://pubmed.ncbi.nlm.nih.gov/27959697/
 (Accessed February 15, 2024).
- Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E,
 Spector E, et al. 2015. Standards and guidelines for the interpretation of sequence
 variants: a joint consensus recommendation of the American College of Medical Genetics
 and Genomics and the Association for Molecular Pathology. *Genet Med* 17: 405–424.
 https://www.ncbi.nlm.nih.gov/pubmed/25741868.
- Riggs ER, Andersen EF, Cherry AM, Kantarci S, Kearney H, Patel A, Raca G, Ritter DI, South
 ST, Thorland EC, et al. 2020. Technical standards for the interpretation and reporting of
 constitutional copy-number variants: a joint consensus recommendation of the American
 College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource
- 811 (ClinGen). *Genetics in Medicine* 22: 245–257. https://pubmed.ncbi.nlm.nih.gov/31690835/
 812 (Accessed September 8, 2020).
- Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP. 2011.
 Integrative genomics viewer. *Nat Biotechnol* 29: 24–26.
- 815 https://pubmed.ncbi.nlm.nih.gov/21221095/ (Accessed February 15, 2024).
- Sakamoto M, Kurosawa K, Tanoue K, Iwama K, Ishida F, Watanabe Y, Okamoto N, Tsuchida
 N, Uchiyama Y, Koshimizu E, et al. 2024. A heterozygous germline deletion within USP8
 causes severe neurodevelopmental delay with multiorgan abnormalities. *J Hum Genet* 69:
- 819 85–90. http://www.ncbi.nlm.nih.gov/pubmed/38030753 (Accessed February 13, 2024).
- Sanghvi R V., Buhay CJ, Powell BC, Tsai EA, Dorschner MO, Hong CS, Lebo MS, Sasson A,
 Hanna DS, McGee S, et al. 2018. Characterizing reduced coverage regions through
 comparison of exome and genome sequencing data across 10 centers. *Genet Med* 20:
 855–866. https://pubmed.ncbi.nlm.nih.gov/29144510/ (Accessed February 5, 2024).
- 824 Schobers G, Schieving JH, Yntema HG, Pennings M, Pfundt R, Derks R, Hofste T, de Wijs I,
 825 Wieskamp N, van den Heuvel S, et al. 2022. Reanalysis of exome negative patients with
- rare disease: a pragmatic workflow for diagnostic applications. *Genome Med* **14**.
- Sobreira N, Schiettecatte F, Valle D, Hamosh A. 2015. GeneMatcher: a matching tool for
 connecting investigators with an interest in the same gene. *Hum Mutat* 36: 928–30.
 http://doi.wiley.com/10.1002/humu.22844 (Accessed November 25, 2018).
- Sobreira NLM, Arachchi H, Buske OJ, Chong JX, Hutton B, Foreman J, Schiettecatte F, Groza
 T, Jacobsen JOB, Haendel MA, et al. 2017. Matchmaker Exchange. *Curr Protoc Hum Genet* 95: 9.31.1-9.31.15. http://doi.wiley.com/10.1002/cphg.50 (Accessed November 25, 2018).
- 834 Srivastava S, Love-Nichols JA, Dies KA, Ledbetter DH, Martin CL, Chung WK, Firth H V.,
- 835 Frazier T, Hansen RL, Prock L, et al. 2019. Meta-analysis and multidisciplinary consensus
- 836 statement: exome sequencing is a first-tier clinical diagnostic test for individuals with

- 837 neurodevelopmental disorders. *Genet Med* **21**: 2413–2421.
- 838 https://pubmed.ncbi.nlm.nih.gov/31182824/ (Accessed December 6, 2022).
- 839 Wagner J, Olson ND, Harris L, McDaniel J, Cheng H, Fungtammasan A, Hwang YC, Gupta R,
- 840 Wenger AM, Rowell WJ, et al. 2022. Curated variation benchmarks for challenging
- 841 medically relevant autosomal genes. *Nat Biotechnol* **40**: 672–680.
- 842 https://pubmed.ncbi.nlm.nih.gov/35132260/ (Accessed February 15, 2024).
- 843 Wenger AM, Peluso P, Rowell WJ, Chang PC, Hall RJ, Concepcion GT, Ebler J,
- Fungtammasan A, Kolesnikov A, Olson ND, et al. 2019. Accurate circular consensus long-
- read sequencing improves variant detection and assembly of a human genome. *Nat*
- 846 *Biotechnol* **37**: 1155–1162.
- 847